TY - JOUR T1 - Characterizing relevant microRNA editing sites in Parkinson’s disease JF - medRxiv DO - 10.1101/2020.04.06.20054791 SP - 2020.04.06.20054791 AU - Chenyu Lu AU - Shuchao Ren AU - Zhigang Zhao AU - Xinwan Wu AU - Angbaji Suo AU - Nan Zhou AU - Jun Yang AU - Tianqing Li AU - Chao Peng AU - Yun Zheng Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/11/2020.04.06.20054791.abstract N2 - MicroRNAs (miRNAs) are extensively edited in human brains. However, the functional relevance of miRNA editome is largely unknown in Parkinson’s disease (PD). By analyzed small RNA sequencing profiles of brain tissues of 43 PD patients and 88 normal controls, we totally identified 421 miRNA editing sites with significantly different editing levels in prefrontal cortices of PD patients (PD-PC). A-to-I edited miR-497-5p has significantly higher expression levels in PD-PC compared to normal controls and directly represses OPA1 and VAPB, which potentially contributes to the progressive neurodegeneration of PD patients. These results provide new insights into mechanistic understanding, novel diagnostic and therapeutic clues of PD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was supported in part by two grants (No. 31760314) of National Natural Science Foundation of China and a grant (No. 2018YFA0108502) of the Ministry of Science and Technology of China to YZ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study were available at the NCBI SRA and GEO databases at https://www.ncbi.nlm.nih.gov/sra and https://www.ncbi.nlm.nih.gov/geo/. ER -